Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-823-1 | CAS number: 55514-22-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study not performed according to GLP, but carried out in a quality environment and in repect of internal standard operating procedures, checked by regular Quality Assurance audits, and according to OECD 402 and 404 guidelines.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- GLP compliance:
- no
- Remarks:
- But audited by Quality Assurance
- Test type:
- fixed dose procedure
- Limit test:
- yes
Test material
- Reference substance name:
- 3-[4-(5,6-diphenyl-1,2,4-triazin-3-yl)phenyl]-5,6-diphenyl-1,2,4-triazine
- EC Number:
- 700-823-1
- Cas Number:
- 55514-22-2
- Molecular formula:
- C36H24N6
- IUPAC Name:
- 3-[4-(5,6-diphenyl-1,2,4-triazin-3-yl)phenyl]-5,6-diphenyl-1,2,4-triazine
- Details on test material:
- - Name of test material (as cited in study report): CH022 WP30
- Physical state: powder
- Analytical purity: 99.8 %
- Purity test date: January 7th, 2012
- Lot/batch No.: LP140
- Stability under test conditions: stable
- Storage condition of test material: at room temperature in a dark and well ventilated place
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Janvier, Le Genest-Saint-Isle, France
- Weight at study initiation: males: approximately 250 g, females: approximately 200 g
- Housing: 1 animal per cage
- Diet: ad libitum
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/-2
- Humidity (%): between 40 and 70
- Air changes (per hr): > 10 full air changes
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: 6 x 5 cm
- % coverage: 10 %
- Type of wrap if used: Gauze patch held in close contact with the skin by means of a non occlusive tape Micropore
REMOVAL OF TEST SUBSTANCE
- Washing (if done): the testsite was wiped with a cotton pad soaked with purified water
- Time after start of exposure: 24 +/- 1 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): direct application of 2000 mg/kg bw
- For solids, paste formed: no - Duration of exposure:
- 24 +/- 1 hours
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5 males and 5 females
- Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations: once daily during acclimation period and for 15 days after application, but on Day 1: 1h, 3h, ad 5 hours after application.
- Frequency ofweighing: on Day 1 (before application), and on days 3, 8, 15.
- Necropsy of survivors performed: yes
- A complete macroscopic examination was performed on all animals. This included examination of the thoracic, abdominal and pelvic cavities with their associated organs and tissues.
- skin examination according to OECD 404, for skin irritation checking
Results and discussion
- Preliminary study:
- The dose was selected considering 2000 mg/kg did not induce mortality by oral route and in vitro skin penetration of WP30 using human skin mounted on static cells did not exceed 0.49 %.
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- None
- Clinical signs:
- other: No anomaly detected
- Gross pathology:
- None
Applicant's summary and conclusion
- Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- As no mortality was observed, DL50 by dermal application is above 2000 mg/kg.
- Executive summary:
The objective of this study was to evaluate the potential toxicity of the test item CH0222 WP30 after a single topical application for a 24-hour exposure period on Wistar rat skin.
5 male and 5 female Wistar rats (RjHan: WI, SPF albino rats from Janvier) were treated at 2000 mg/kg corresponding to the limit test.
On the day of application (Dl), a weight based quantity of test item was moistened with purified water and applied directly onto the dorsal part of the trunk of each animal which had been clipped the day before. The test item was evenly spread over the application site which represented at least lO% of the body surface. The application site was then covered with a gauze patch held in close contact with the skin by means of a non occlusive tape for a 24h exposure period. At the end of the exposure period, the patch was removed and the test site was wiped with a cotton pad soaked with purified water.
Animals were observed at least once daily for mortality and general clinical signs for 15 days and were weighed on Dl, D3, D8 and D15.
Skin reactions were evaluated for all animals approximately 1 hour (D2), 24h (D3), 48h (D4) and 72h (DS) after patch removal at the end of the contact period and on D8 and Dll. The responses, erythema and edema, were scored according to a table graded from 0 (no skin reaction) up to 4 (severe reaction).
No death occurred during the course of the study and no abnormal clinical sign was observed.
Body weight evolution was not affected by the treatment for males whereas a slight body weight loss was observed in 4/5 females between Dl and D3 but weight increase was restored thereafter. This transient observation on body weight evolution was most probably related to the non occlusive tape.
.
As no mortality was observed, CH0222 WP30 is not classified and the DL 50 by dermal application was estimated to be higher than 2000 mg/kg.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.